Kinetic Profiling of <i>RAS</i> Mutations With Circulating Tumor DNA in the Canadian Cancer Trials Group CO.26 Trial Suggests the Loss of <i>RAS</i> Mutations in Neo-<i>RAS</i>-Wildtype Metastatic Colorectal Cancer Is Transient
We identified a 3.2%-6.3% prevalence of the neo-<i>RAS</i>-WT phenomenon in the CO.26 trial. However, 67% of apparent cases were transient with subsequent re-emergence.
Authors
- Daniel J. Renouf (ORCID: https://orcid.org/0000-0002-7597-6089)
- Harriet Feilotter (ORCID: https://orcid.org/0000-0002-1388-2183)
- Chris J. O’Callaghan (ORCID: https://orcid.org/0000-0003-2896-666X)
- Florence T.H. Wu (ORCID: https://orcid.org/0000-0002-6439-4606)
- Hagen Fritz Kennecke (ORCID: https://orcid.org/0000-0002-3211-0656)
- Dongsheng Tu (ORCID: https://orcid.org/0000-0003-4842-2184)
- Derek J. Jonker (ORCID: https://orcid.org/0009-0008-1103-3429)
- Leylah Drusbosky (ORCID: https://orcid.org/0000-0002-9401-4600)
- Jonathan M. Loree (ORCID: https://orcid.org/0000-0001-8189-2132)
- Eric X. Chen (ORCID: https://orcid.org/0000-0002-4581-8848)
- James T. Topham (ORCID: https://orcid.org/0009-0001-6601-8807)
Institutions
- University of British Columbia (CA)
- University of Ottawa (CA)
- Oregon Health & Science University (US)
- Ottawa Hospital (CA)
- Princess Margaret Cancer Centre (CA)
- Guardant (United States) (US)
Publication Details
- Journal
- JCO Precision Oncology
- Published
- 2024-08-01
- DOI
- https://doi.org/10.1200/po.24.00031
- Citations
- 3
- Primary Topic
- Cancer Genomics and Diagnostics
- Type
- article
- Field-Weighted Citation Impact
- 0.86